-
Civica to Manufacture and Distribute Affordable Insulin
- Drastically reducing out-of-pocket costs for insulin through transformative collaboration between Civica and dedicated partners
- New: California selects Civica as its insulin manufacturing partner: Read, Watch.
Our Mission: Provide Quality Generic Medicines that are Available and Affordable to Everyone
- We were created to address drug shortages and high drug prices. Learn about our "novel approach to doing business"
0 Million
Patients treated with Civica medications
These include:
Advocate Aurora Health
Allegheny Health Network
Aspirus Health System
Baptist Health
Baptist Health South Florida
Baylor Scott & White Health
BJC HealthCare
Christiana Care Health System
CommonSpirit Health
Cone Health
Emerson Health
Franciscan Alliance
Gary and Mary West Foundation
Griffin Hospital
Hospital Corporation of America (HCA)
Hospital Sisters Health System
Integris Health
Intermountain Healthcare
Kaiser Permanente
Kootenai Healthcare
Laura and John Arnold Foundation
Mayo Clinic
MemorialCare
Memorial Hermann
Montage Health
Memorial Sloan Kettering Cancer Center
New Hanover Regional Medical Center
NorthBay Healthcare
North Memorial Hospital
NYU Langone Health
Ochsner Health System
Peterson Center on Healthcare
Piedmont Health
Piedmont Health
ProMedica Health
Piedmont Health
Providence St. Joseph Health
Regional One Health
Reid Health
Samaritan Health Services
SCL Health
Sanford Health
SCL Health
Southeast Georgia Health System
Spectrum Health
SSM Health
St. Clair Hospital
Steward Health Care System
St. Luke's University Health Network
The Christ Hospital
ThedaCare
Trinity Health
UnityPoint Health
University of Miami Health
University of Utah Health
U.S. Department of Defense
U.S. Department of Veterans Affairs
VCU Health
Recent News
California Selects Civica Rx as Its Insulin Manufacturing Partner
LEHI, UTAH, March 18, 2023 – Civica Inc. (Civica, Civica Rx) today announced it will manufacture insulins for the State of California’s CalRx Biosimilar Insulin Initiative as part of its insulin manufacturing work. Once approved, Civica’s biosimilar versions of the most commonly used short-and long-acting insulins will be available to Californians and nationwide at...
Civica Welcomes Ypsomed as Injection Pen Partner for Its Affordable Insulin Initiative
Civica, today announced the selection of Ypsomed AG as the manufacturer and supplier of insulin dosing injector pens for Civica’s affordable insulins. As previously announced, Civica plans to produce three insulin biosimilars – glargine, lispro and aspart – each of which will be available both in vials and prefilled pens, and sell the insulins at...
AmerisourceBergen Kicks Off Strategic Relationship with Civica
Starting today, global healthcare company AmerisourceBergen will serve as Civica, Inc.’s (Civica) exclusive distribution partner and provide supply chain support for Civica’s products and a best-in-class customer experience for Civica members. Through its distribution network, AmerisourceBergen will work to ensure that Civica’s crucial products reach its members across the country efficiently, reliably, and securely....
Why Civica?
Over the past two decades, shortages of generic, injectable drugs critical to the lifesaving work of hospitals in the United States have become commonplace. These drug shortages are so ubiquitous that hospitals and health care systems now maintain permanent drug shortage response teams that seek alternatives to unavailable drugs.
As a result, time that hospital pharmacists, technicians, nurses and others would prefer to spend caring for patients is spent ensuring that the patients who most need short-supply drugs get whatever supply is available.
Civica was created to reduce and prevent drug shortages and the price spikes that can accompany them. Its mission is to make quality generic medicines accessible and affordable to everyone.